THE ROLE OF METABOLIC SYNDROME IN THE DEVELOPMENT OF ATHEROSCLEROSIS

Authors

  • Qambarov Azizbek Oybek oglu,Turniyazov Azamat Askarovich RSHTYoIM, Navoi branch, clinical Ordinator Head of the Emergency Cardiology Department of the Navoi Branch of the RSHTYoIM Hospital, a doctor of the highest category

Keywords:

metabolic syndrome, atherosclerosis, insulin resistance, cardiovascular disease, endothelial dysfunction, inflammation, dyslipidemia, central obesity, oxidative stress

Abstract

Metabolic syndrome represents a cluster of interconnected metabolic abnormalities that collectively substantially elevate the risk of atherosclerotic cardiovascular disease. This comprehensive review examines the pathophysiological mechanisms through which metabolic syndrome contributes to the development and progression of atherosclerosis. The syndrome, characterized by central obesity, insulin resistance, dyslipidemia, and hypertension, creates a pro-inflammatory and pro-thrombotic environment that accelerates endothelial dysfunction and plaque formation. Current evidence demonstrates that each component of metabolic syndrome independently contributes to vascular damage, while their combination produces synergistic deleterious effects. The prevalence of metabolic syndrome continues to increase globally, reaching approximately twenty five percent of the world adult population, creating an urgent public health challenge . This review synthesizes current understanding of the molecular pathways linking metabolic syndrome to atherosclerosis, including insulin resistance signaling disruption, adipokine imbalance, endoplasmic reticulum stress, oxidative stress, and chronic low-grade inflammation. Additionally, this paper examines clinical evidence from epidemiological studies and intervention trials, discusses diagnostic challenges, and explores therapeutic strategies targeting both individual components and shared underlying mechanisms. Understanding these complex interactions is essential for developing effective prevention and treatment approaches for the growing population at risk.

Downloads

Download data is not yet available.

References

Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches. Frontiers in Nutrition. 2025;12:1661603.

Association between Metabolic Syndrome Score and Subclinical Atherosclerosis. Reviews in Cardiovascular Medicine. 2025;26(3):26811.

Molecular Mechanisms of Metabolic Syndrome. BADERC Research Profile. 2025.

Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients with Metabolic Syndrome. Journal of Carcinogenesis. 2025;24(3S):441-448.

The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases. Hormone and Metabolic Research. 2024;56(10):683-696.

Stratification of Atherosclerosis based on Plasma Metabolic States. Journal of Clinical Endocrinology and Metabolism. 2024;109(5):1250-1262.

Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome. Diabetology and Metabolic Syndrome. 2025;17:245.

Evolocumab Reduces CV Events, LDL-C in Patients with Metabolic Syndrome on Statins. HCPLive. 2020.

Advances in Metabolomics: A Comprehensive Review of Type 2 Diabetes and Cardiovascular Disease Interactions. International Journal of Molecular Sciences. 2025;26(8):3562.

Metabolic syndrome and premature atherosclerotic cardiovascular disease: insights for the individual and the population. European Journal of Preventive Cardiology. 2024;31(10):1189-1192.

Downloads

Published

2026-02-22

How to Cite

Qambarov Azizbek Oybek oglu,Turniyazov Azamat Askarovich. (2026). THE ROLE OF METABOLIC SYNDROME IN THE DEVELOPMENT OF ATHEROSCLEROSIS. Journal of Applied Science and Social Science, 16(02), 1071–1080. Retrieved from https://www.internationaljournal.co.in/index.php/jasass/article/view/3420